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Abstract
Background: Dynamic Wave Arc (DWA) is a clinical approach designed to maximize the versatility of Vero SBRT
system by synchronizing the gantry-ring noncoplanar movement with D-MLC optimization. The purpose of this
study was to verify the delivery accuracy of DWA approach and to evaluate the potential dosimetric benefits.
Methods: DWA is an extended form of VMAT with a continuous varying ring position. The main difference in the
optimization modules of VMAT and DWA is during the angular spacing, where the DWA algorithm does not
consider the gantry spacing, but only the Euclidian norm of the ring and gantry angle. A preclinical version of
RayStation v4.6 (RaySearch Laboratories, Sweden) was used to create patient specific wave arc trajectories for 31
patients with various anatomical tumor regions (prostate, oligometatstatic cases, centrally-located non-small cell
lung cancer (NSCLC) and locally advanced pancreatic cancer-LAPC). DWA was benchmarked against the current
clinical approaches and coplanar VMAT. Each plan was evaluated with regards to dose distribution, modulation
complexity (MCS), monitor units and treatment time efficiency. The delivery accuracy was evaluated using a 2D
diode array that takes in consideration the multi-dimensionality of DWA during dose reconstruction.
Results: In centrally-located NSCLC cases, DWA improved the low dose spillage with 20 %, while the target
coverage was increased with 17 % compared to 3D CRT. The structures that significantly benefited from using DWA
were proximal bronchus and esophagus, with the maximal dose being reduced by 17 % and 24 %, respectively. For
prostate and LAPC, neither technique seemed clearly superior to the other; however, DWA reduced with more than
65 % of the delivery time over IMRT. A steeper dose gradient outside the target was observed for all treatment sites
(p < 0.01) with DWA. Except the oligometastatic cases, where the DWA-MCSs indicate a higher modulation, both
DWA and VMAT modalities provide plans of similar complexity. The average ɣ (3 % /3 mm) passing rate for DWA
plans was 99.2 ± 1 % (range from 96.8 to 100 %).
Conclusions: DWA proven to be a fully functional treatment technique, allowing additional flexibility in dose
shaping, while preserving dosimetrically robust delivery and treatment times comparable with coplanar VMAT.
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Background
In the past few years, there has been a widespread adop-
tion of rotational beam-delivery techniques into the
clinic. With more degrees of freedom during treatment,
advanced arc deliveries provide a larger flexibility in
shaping dose distributions while obtaining more time-
efficient deliveries than with stationary beams. Currently,
volumetric modulated arc therapy (VMAT) is one of the
most advanced delivery techniques, simultaneously inte-
grating multi-leaf collimator (MLC) field shape modula-
tion with gantry speed and dose rate variation. Dose
delivery by VMAT may further be optimized by increas-
ing the degrees-of-freedom. More specifically, techno-
logical evolutions have brought the use of noncoplanar
arc delivery within reach of clinical application.
For noncoplanar VMAT by dynamic couch rotation,
several groups have already reported dosimetric
advantages for different treatment sites, hereby the
couch and gantry following either a user-defined tra-
jectory [1, 2] or a directly optimized trajectory [3–6].
However, to the authors’ knowledge, none of the
stated delivery approaches are commercially available
or implemented in a conventional clinical workflow.
Dynamic Wave Arc (DWA) is a clinical arc approach
designed to maximize the noncoplanar versatility of
Vero SBRT system by combining the gantry-ring syn-
chronized rotation with D-MLC optimization. The speed
of the gantry and ring can be accurately modulated due
to the rigid gear transmission design, which allows the
system to preserve its rigidity even during complex
gantry-ring movements. The theoretical concept of
DWA was presented by Mizowaki et al. [7] under the
term “3D unicursal irradiation” and the technique was
subject to other more technically orientated reports re-
garding geometrical and dosimetric accuracy [8, 9].
This paper describes the implementation of DWA
following a standard clinical workflow by integrating
a dedicated commercially-available treatment planning
system (TPS) on the Vero SBRT treatment platform.
The optimization algorithm for DWA planning was
validated and characterized by comparing it with the
standard coplanar VMAT optimizer. The first results
of applying DWA on different treatment sites are pre-
sented. Subsequently the DWA/VMAT delivery accur-
acy was evaluated using a diode array which takes the




Thirty-one patients with various anatomical tumor re-
gions were selected from the Vero database. Based on its
high incidence for radiation therapy, prostate cancer and
SBRT for oligometastases pathologies were selected for
this study. Additionally, some more challenging cases
regarding the avoidance of organs-at-risk (OAR), i.e.
centrally-located non-small cell lung cancer (NSCLC)
and locally-advanced pancreatic cancer (LAPC) were
Table 1 Overview of the patient data related to treatment indication and fractionation. The physics dose limitations for the most
common OARs are included together with the delivery technique clinically used in our center








Prostate 3 78Gy(2Gy/fx) >90 % 171.8
[129.8-222.8]
Rectum D2% < 74.1 Gy
V70.2Gy < 25 %











V20Gy < 25 %
V30Gy < 30 %


















D2% < 30 Gy
D2% < 26 Gy
D2% < 34 Gy
D2% < 34 Gy
V20Gy < (8-10)%
8-10 CRT beams
LAPC 10 48Gy(3.2Gy/fx) >95 % 188.5
[140.6-257.2]
Duodenum V39Gy < 1.0 cc





V39Gy < 1.0 cc
V36Gy < 10 cc
V20Gy < 30 %
Dmean < 30 Gy
aat 80%isodose
bvariable isodose prescriptions
Abbreviations: NSCLC, centrally-located non-small cell lung cancer; LAPC, locally-advanced pancreatic cancer; PD, prescription dose; D2% near-maximum dose i.e.
maximum dose to 2 % of the volume; Vxx%, percentage of the volume receiving ≥ xx Gy; VxxGy volume of the structure receiving ≥ xx Gy; Dmean, mean dose
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added considering that a maximum OAR sparing can po-
tentially reduce treatment-toxicity. Table 1 summarizes the
treatment indications and fractionation, along with the
main OAR dose limitations. For the prostate, the clinical
target includes the prostate gland with the base of seminal
vesicles. The PTV was created adding a uniform 6 mm ex-
pansion, while the rectum was the main critical OAR. The
oligometastatic patients are part of a prospective clinical
trial [10], and include multiple (≤3) lung and liver lesions.
The planning constraints of SBRT for centrally-located
NSCLC were adopted from the RTOG 0813 guidelines.
The pancreatic cases were outlined using the ITV approach
[11, 12]. The dose-limiting OARs (duodenum, stomach)
were contoured with a planning risk margin of 3 mm to
accomplish the gastro-intestinal dose constraints.
B. DWA characterization
A preclinical version of RayStation v4.6 (RaySearch La-
boratories, Sweden) was used to create patient-specific
DWA trajectories on the Vero SBRT system in order to
develop site-specific class solutions for the final product.
A wave trajectory is defined by 5 to 8 manipulation
points (MPs) that are gantry-ring angle positions where
the direction of the ring rotation can change. The MPs
were selected to minimize overlap between PTV and or-
gans at risk through beam's eye view (BEV) inspection
by a human planner, while remaining within the ring-
table collision limitations provided by the manufacturer.
According to the TPS vendor’s specifications, the dom-
inant angle is either the ring or gantry angle, depending
on which has the largest angle span, and is determined
per sub-arc (defined by two consecutive MPs). The dom-
inant angle should be a multiple of 4° and the minimum
angular distance per sub-arc should be 24°. An add-
itional constraint of 1 degree ring rotation per gantry de-
gree was enforced in the optimization algorithm, to
avoid creating too “steep” sub-arcs in terms of ring rota-
tion with respect to gantry rotation.
DWA is an extended form of VMAT with a con-
tinuous variable ring position. The user sets up the
dose-volume objective functions in the same way as
VMAT, however the optimization starts with beam
generation at 24° increments along the predefined
wave trajectory. A fluence map optimization follows
and, at each initial angle, 2-4 segments are generated and
filtered so that there are only two control points (CP) per
beam angle. The CPs are linearly interpolated from the
adjacent CPs and equally distributed between them. After
the MLC segments are created, a direct machine param-
eter optimization (DMPO) (13) algorithm is applied con-
sidering the following DWA specific machine constraints:
gantry speed (0.1-6°/s), ring speed (0.1-2.5°/s), dose rate
(150-400 MU/min), and MLC leaf speed (0.1–4 cm/s).
The algorithm incorporates the dose rate into the
optimization process by selecting its value from a discrete
look-up table. While the ring speed is modulated per sub-
arc, the optimizer assumes constant gantry speed and con-
stant dose rate throughout the arc to achieve constant
MU per CP. The dose calculation engine is based on the
collapsed cone convolution superposition algorithm.
These machine constraints are similar for coplanar
VMAT on the Vero system, i.e. constant dose rate and
constant gantry speed (VMATCDR) [13, 14]. The main
difference in the optimization modules of VMATCDR
and DWA is the angular spacing of control points,
where the DWA algorithm does not consider the gantry
spacing, but the Euclidian norm of the ring and gantry.
C. Treatment scenarios and dosimetric benchmark
Figure 1 gives an overview of the treatment scenar-
ios investigated, along with a comprehensive descrip-
tion for each one. The clinical delivery techniques
presented in Table 1 were considered as reference
and were compared with DWA and VMATCDR.
The planning objectives for target volumes and OARs
were individualized for each patient, but kept identical be-
tween VMATCDR and DWA. For multiple lesions, one arc
per lesion was used and all targets were simultaneously
optimized. Due to the PTV-OAR overlap and complex
geometry in the LAPC cases, two independent DWA tra-
jectories were customized mostly to take advantage of the
gantry-ring collision-free space. For prostate, single-arc
treatment was employed for both DWA and VMATCDR.
Each plan was evaluated with regard to the target
coverage, dose to OAR, monitor units (MU) and
treatment delivery time. The PTV coverage was
defined by the ratio between target volume within
the prescription isodose and PTV volume. The low
dose spillage describes the ratio between the vol-
ume receiving 50 % of the prescription dose and
the PTV volume. The planning techniques were
compared using a paired two-tailed Student’s t-test,
with p < 0.05 considered as statistically significant.
D. DWA performance validation
The DWA/ VMATCDR dosimetric tests were performed
on a Vero research machine (BrainLAB, Germany) fea-
turing a software and hardware upgrade to support
DWA and VMAT deliveries. Essentially, the machine’s
capability to perform a faster dynamic MLC leaf move-
ment (i.e. 4 cm/s at isocenter level) was activated. The
R&V system is able to recognize DWA plans, while the
controller allows gantry-ring synchronous rotations.
The quality of the generated DWA plans was
assessed using the Delta4 diode array phantom
(ScandiDos, Sweden) [15–17] and a preclinical soft-
ware version which supports automatically import of
gantry-ring angular positions per CP from the
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DICOM RT plan. During measurement the dose
pulses are sorted into these CPs according to the
planned number of MU per CP. The corresponding
angular correction factors are being applied for each
CP during dose reconstruction and the agreement
score with DWA dose from the TPS was derived by
calculating the minimum 3D gamma index for each
diode point in the orthogonal 2D planes. For a spe-
cific diode in the 2D planes, the software includes
the full planned 3D dose in the whole phantom
volume to find the minimum gamma index. A global
3 % dose difference and 3 mm distance-to-agreement
criteria was used, with a lower threshold level of
20 % of the maximum expected dose.
The DWA/VMATCDR complexity was quantified by
using the modulation complexity score (MCS) proposed
by Masi et al. [18, 19]. The MCS computation takes in
consideration the product of mean values between adja-
cent CPs of leaf sequence variability and aperture area
variability, weighted by the relative MU delivered be-
tween two consecutive CPs and then summed over all
CPs in the arc. Its value ranges between 0 and 1, where
1 means no complexity.
In order to clarify possible discrepancies between
planning and physical machine performance, the TPS
estimations were compared with the actual DWA
LogFiles recorder by the machine’s controller during
delivery at an increased sampling rate of 100Hz
(~10 ms). The most relevant information in the
DWA LogFile is the gantry-ring speed profiles and
the dose rate profile. It is worth mentioning that in
the TPS, the ring speed variation per sub-arc is inte-
grated, while the gantry speed and dose rate are
assumed constant over the entire wave. However, the
controller recalculates and adjusts these three
parameters at each MP in order to have the fastest
delivery [20].
Results
The dose statistics per indication are summarized in
Table 2. Figure 2 shows the OARs diagrams for the
different delivery approaches. The prostate cases
presented comparable plan quality with no signifi-
cant difference in PTV coverage. Similar values were
found for the high doses to the rectum. Rectum
V70.2Gy was 9.7 %, 8.3 %, and 8.1 % for IMRT, DWA
and VMATCDR respectively, while rectum V62.4Gy
was 22.0 %, 19.8 %, and 19.4 %. The arc-based tech-
niques are able to deliver the dose faster, shortening
the treatment time with more than 70 %.
For the oligometastases, all modalities provided
comparable plan qualities, with no significant differ-
ence in PTV coverage or OAR sparing, but with an
improved low dose spillage for DWA (p = 0.01) and
comparable to VMATCDR (p > 0.05). Mean lung doses
and V20Gy presented minimal differences, same for
Fig. 1 Treatment delivery scenarios investigated along with the dose distribution in the axial plane. a) coplanar/ noncoplanar static beams b)
DWA noncoplanar trajectory defined by 7 MPs highlighted in red c) VMATCDR denotes a coplanar arc solution with MLC filed shape modulation,
but constant gantry speed and constant dose rate
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mean liver doses and V30Gy for the liver cases
(Fig. 2a). The number of MU per lesion had an 41 %
increase in DWA and VMATCDR cases versus 3D
CRT; however the delivery time per lesion was
reduced with 37 %.
Compared with 3D CRT, rotational techniques in-
creased target coverage for centrally-located NSCLC,
while keeping the risk structures below dose limits, at
the cost of an increase in MUs of 75 % and delivery time
of 20 % (Table 2). The structures significantly benefitting
from DWA are proximal bronchus (p = 0.04) and
esophagus (p = 0.05), while other OARs present compar-
able values (Fig. 2b). Compared with VMATCDR, DWA
reduced D2% with a mean of 2Gy for proximal bronchus
and esophagus. The clinical consideration of decreased
efficacy versus possible benefit is of course a matter of
debate. TPS estimated times were close to actual deliv-
ery times for both DWA and VMATCDR.
In the LAPC cases, DWA achieved similar PTV
and GTV coverage, with a significantly improved low
dose distribution (p < 0.01) compared to IMRT. The
number of MU was significantly lower for DWA ver-
sus IMRT, and comparable with VMATCDR (Table 2).
The delivery time was reduced by 65 % and 63 % with
DWA and VMATCDR, respectively. The TPS time estima-
tion was overestimated with approx. 21 % for both tech-
niques. The duodenum V36Gy volume is substantially
reduced with DWA compared with IMRT (p = 0.01), but
similar compared to VMATCDR (p = 0.39). No significant
difference was observed for the stomach doses between
the three approaches. The volume of both kidneys exceed-
ing 20Gy was decreased by 26 % over IMRT using DWA
(Fig. 2c).
The MCSs and gamma passing rates for DWA and
VMATCDR are presented in Table 3. Overall investigated
indications, the oligometastatic plans showed the highest
complexity. The DWA-MCSs were significantly lower
compared with VMATCDR –MCSs (p = 0.03). No mean-
ingful difference was observed between MCSc of DWA
and VMATCDR for centrally-located NSCLC (p = 0.34),
prostate (p = 0.42) or LAPC (p = 0.29), respectively. The
DWA plans presented a good agreement between
Table 2 Summary of the results of the target volume dose distribution and delivery parameters for all investigated scenarios
Site 3D CRT/IMRT DWA VMATCDR
Mean ± SD p-value Mean ± SD p-value Mean ± SD
Prostate
n = 3
Coverage PTV D90% 0.99 ± 0.01 p = 0.95 0.98 ± 0.03 p = 0.90 0.98 ± 0.03
Low dose spillage 3.99 ± 0.21 p = 0.66 3.81 ± 0.22 p = 0.49 4.08 ± 0.58
MU 531 ± 45 p = 0.24 495 ± 2 p = 0.36 463 ± 54
Estimated time (min) - - 3.09 ± 0.02 p < 0.01 1.51 ± 0.13





Coverage PTV D80% 0.96 ± 0.1 p = 0.27 0.98 ± 0.05 p = 0.35 0.97 ± 0.07
Low dose spillage 5.98 ± 2.33 p = 0.01 4.87 ± 1.23 p = 0.25 5.03 ± 1.03
MU 975 ± 211 p < 0.01 1370 ± 346 p = 0.29 1320 ± 309
Estimated time (min) - - 3.80 ± 1.41 p = 0.16 3.51 ± 0.80




Coverage PTV D95% 0.84 ± 0.20 p = 0.21 0.91 ± 0.06 p = 0.26 0.90 ± 0.09
Low dose spillage 5.39 ± 1.24 p = 0.01 4.43 ± 1.06 p = 0.11 4.58 ± 1.02
MU 1885 ± 477 p < 0.01 3349 ± 896 p = 0.29 3238 ± 809
Estimated time (min) - - 8.36 ± 1.83 p = 0.61 8.36 ± 1.98
Actual time (min) 7.08 ± 1.09 p = 0.18 8.45 ± 2.32 p = 0.90 8.59 ± 2.29
LAPC
n = 10
Coverage PTV D98% 0.71 ± 0.23 p = 0.59 0.76 ± 0.13 p = 0.94 0.76 ± 0.15
Coverage GTV D95% 0.81 ± 0.17 p = 0.53 0.85 ± 0.15 p = 0.10 0.85 ± 0.18
Low dose spillage 3.70 ± 0.28 p < 0.01 3.25 ± 0.22 p = 0.90 3.34 ± 0.22
MU 1091 ± 100 p < 0.01 644 ± 65 p = 0.10 704 ± 87
Estimated time (min) - - 3.10 ± 0.15 p = 0.34 3.16 ± 0.20
Actual time (min) 6.83 ± 0.41 p < 0.01 2.42 ± 0.01 p = 0.63 2.51 ± 0.28
Note: The data is presented as mean values ± SD. The statistical difference between 3D CRT vs. DWA and DWA vs. VMATCDR are presented in the first and second
p-value columns, respectively Estimated time = TPS approximation based on the dose rate assigned during optimization; Actual time =measured beam-on delivery
time.
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measured and calculated dose, with an average ɣ(3 %/3
mm) passing rate of 99.2 ± 1 % (range from 96.8 % to
100 %). The VMATCDR average γ (3 %/3 mm) passing
rate was 98.4 ± 1.4 % (range from 96.4 % to 100 %).
Figure 3 presents the gantry-ring angular velocity esti-
mated by the TPS (Fig. 3a) for a pancreatic case, bench-
marked with the actual values recorded by the LogFiles
in function of time (Fig. 3b). The mean gantry-ring
speed values from the LogFiles were 4.78°/s and 2.99°/s,
while the TPS estimated mean values were 3.55°/s and
1.55°/s, respectively. Figure 3c shows the dose rate
discrepancy between TPS approximation (180MU/min)
and actual used value (≈243 MU/min), difference that
contributes to a delivery time overestimation of 26 %.
The dose rate modulation behavior in synchrony with
the mechanical stopping motion of the system, quanti-
fied to 0.1 s can also be observed in Fig. 3c.
Discussion
Several investigators have reported that noncoplanar
beam/arc arrangements improve dosimetric quality;
Fig. 2 Dose statistics for the most common OARs in a) oligometastases, b) centrally-located NSCLC and c) LAPC
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however its clinical usability is considered rather contro-
versial. Recently, Wild et al. [21] compared nine different
treatment scenarios based on plan quality and delivery ef-
ficiency, and concluded that noncoplanar Step&Shoot
IMRT beams and VMAT applying optimized, arbitrary,
noncoplanar trajectories are valuable clinical approaches.
Clinical implementation of DWA is a viable option
due to the following factors: added variable angles of
orientation; no customized workflow required; delivery
time comparable with coplanar VMATCDR. The objec-
tions against couch rotation during VMAT delivery with
an L-shape LINAC are mostly focused on possible pa-
tient movement during beam on, which is difficult to
predict or adapt for. Re-verification of the patient setup
after or during rotation of the couch is therefore cur-
rently required in clinical routine [22, 23]. The Wave
Arc planning module allows one to design individualized
patient treatments, while the Vero’s hardware controller
ensures a continuous reliable delivery [8, 9]. No add-
itional patient immobilization is required other than that
already employed in clinical routine, since the O-ring
design allows two-dimensional movements without any
couch maneuvering. There are no patient-specific anti-
collision rules enforced by the software, however this
can be compensated by manual verification performed
using the control pendant inside the treatment room to
run wave trajectories without beam-on.
In comparison with 3D CRT, DWA presented a
steeper dose fall-off and improved target coverage. In
the centrally-located NSCLC cases, the mean reduction
in normal tissue exposed to ≥50 % of the prescription
dose was 20 %, while the target coverage was increased
with 17 %. The direct aperture optimization is able to
better shape the dose around targets, which are in close
proximity or overlapping with one or more OARs,
whereas the non-coplanarity maintains low doses to the
lung. For prostate and LAPC, neither technique seemed
clearly superior to the other. However, considering that
Vero cannot perform a collimator rotation, DWA would
be recommended in practice while treating these indica-
tions. The different ring rotations during DWA would
“act as a collimation variation”, increasing the conformal
shaping capabilities for irregular-shaped target volumes
and at the same time minimizing the cumulative effects
of the tongue-and-groove and interleaf transmission [24,
25]. The course of treatment was considerably shortened
with DWA for all indications investigated, except for
centrally-located NSCLC SBRT where it was slightly in-
creased due to the higher MUs per fraction and the
MLC sequence complexity.
The estimated treatment time was frequently longer
than the actual time due to the conservative DWA mod-
ule, that is optimized based on Vero machine’s specifica-
tions with constant dose rate and constant gantry speed.
The delivery time presented in RayStation TPS for the
Vero machine is not to be seen as the estimated delivery
time, rather as a feasible delivery time. The gantry speed
and ring speed displayed in the user interface are pre-
sented to give information on how the time dependence
is modelled in the TPS. The optimizer creates a plan that
is possible to deliver using the selected delivery time i.e.
combination of gantry speed and dose rate. The control-
ler of the Vero machine might (and will in most cases)
select another gantry speed to optimize the delivery per-
formance, independent of the TPS (which provides a de-
liverable plan with feasible MUs per CPs). A descriptive
representation of the controller’s complex adjustments
during DWA is presented in Fig. 3, where the dose rate
and gantry-ring speed ratio readjustment per sub-arc
can be observed. At each MP, the dose rate was reduced
to ~100 MU/min, introducing an overall decrease in the
cumulative MUs of 0.23MU with negligible effects on
Table 3 Site summary for modulation complexity scores and gamma passing rates. The data is presented as mean values ± SD
DWA VMATCDR
mean ± SD mean ± SD p-value
Prostate MCS 0.46 ± 0.02 0.49 ± 0.06 p = 0.42
Ɣ-index (%) 98.17 ± 0.86 98.4 ± 1.71 p = 0.97
Oligometastatic cases MCS 0.28 ± 0.05 0.32 ± 0.05 p = 0.03
Ɣ-index (%) 98.72 ± 1.13 98.42 ± 1.42 p = 0.08
Centrally- located NSCLC MCS 0.33 ± 0.07 0.35 ± 0.09 p = 0.34
Ɣ-index (%) 99.2 ± 0.91 98.54 ± 1.83 p = 0.96
LAPC MCS 0.46 ± 0.04 0.44 ± 0.04 p = 0.29
Ɣ-index (%) 98.1 ± 0.74 98.20 ± 0.70 p = 0.80
Abbreviations: MCS, modulation complexity scores; Ɣ (3 %/3 mm), index gamma passing rate representing the agreement score between calculated and measured
dose distributions; p-value, statistical output of the student t-test
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Fig. 3 Angular gantry-ring velocity profile and dose rate profile for a pancreatic DWA plan (with 301MU). a) gantry-ring angular velocity in
function of delivery time TPS estimated per CP b) gantry-ring angular velocity in function of delivery time acquired by the machine’s controller
c) dose rate profile comparing TPS estimated and actual dose rate variation. The ring angular rotation was used as a common base in each figure
to indicate the directional change during DWA delivery
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the actual dose. The Vero’s control system always aims
for the fastest delivery, as such the highest dose rate is
selected by default, which is decreased when ring speed
is a limiting factor [20].
As DWA and VMATCDR employ nearly identical
optimization modules, with the planning objectives be-
ing kept alike, the modest dosimetric improvements can
be attributed to the noncoplanar geometry. It is worth
mentioning that, from the total number of CPs per
DWA, only approx. 30 % have a ring rotation larger than
15°. Wild et al. [21] results indicated that 9-beam en-
semble were clearly superior compared to five, while 13-
beam ensemble showed only small plan quality improve-
ments. Dong et al.[26] showed that more than 10 couch
kicks are needed to enlarge noncoplanar solution space
and to have notable dose decrease.
DWA and VMATCDR modalities provide plans of simi-
lar complexity, MLC leaf velocity being the leading par-
ameter during optimization. The DWA-MCSs indicated
a higher complexity only in the oligometastatic cases.
Because of an extra degree of freedom in terms of gantry
positions with respect to the cranio-caudal axis along
the patient, multiple coplanar lesions are treated in the
same BEV of each arc more frequently than for
VMATCDR. This can be avoided during planning by cre-
ating independent beam sets for each lesion, such that
the optimization will be carried out looking only at the
dose of the separate beam set.
The calibration of the Delta4 was limited on the
Vero system due to its 15x15 cm2 field size. The
dosimeter relative and directional calibration were
performed on another LINAC, and it can contribute
to the dose discrepancies found in this work [17].
Despite the differences between the TPS and ma-
chine delivery, the DWA planned versus delivered
dose distributions presented an average agreement
above 98 % for all indications, DWA presenting
comparable level of agreement with coplanar
VMATCDR. The Picket Fence test showed that the
noncoplanar gantry-ring motion doesn’t affect the
MLC performance (Additional file 1: Figure S1). To
author’s knowledge, the ring angle variation per con-
trol point could not be integrated in the dose recon-
struction of other 3D dosimetry phantoms. However,
during the QA preparation process, the DWA plan
can be mapped with all ring angles collapsed at 0,
creating a classical coplanar VMAT which can be
verified with common dosimetric phantoms available
in the clinic.
For the moment, there is no module to optimize
the Wave Arc trajectory directly based on dose
criteria. A comparison of the current template-based
approach against a geometric optimization of the
DWA path is required to investigate if further
improvement in therapeutic dose delivery can be
provided by DWA. Nevertheless, considering the
collision-free turning space of the O-ring gantry, a
significant impact of inverse trajectory optimization
is not expected.
The LINAC’s montage on a gimbals mechanism
allows real-time tumor tracking delivery (RTTT),
clinically implemented for conformal beams [11] and
IMRT [12]. RTTT during DWA treatment would be
a feasible extension addressing the motion management
issue for abdominal tumors, since the movement of
the gimbaled X-ray head and the O-ring gantry are
independent.
Conclusion
DWA combines direct machine parameter optimization
with noncoplanar geometry, allowing additional flexibil-
ity in dose shaping. This study describes a preparation
towards the first noncoplanar DWA treatment in clinical
circumstances on the Vero system using a clinical RayS-
tation TPS. The Vero DWA solution proven to be a fully
functional treatment technique, and presented delivery
times comparable with coplanar VMATCDR. The initial
dosimetric assessment with a 2D array provided accept-
able results, however further investigations into the non-
coplanar specificity of the DWA will be performed prior
to clinical implementation.
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